ABSTRACT
Whole genome sequencing (WGS) is used extensively in identifying SARS-CoV-2 variants. However, this method requires stringent sample acceptance criteria, long turn-around time (TAT), expensive processing and maintenance costs, and highly skilled staff. Although sequencing offers comprehensive pathogen insights, a cost-effective tool with faster TAT is beneficial in detecting SARS-CoV-2 variants of concern (VOCs). Here, we used a single nucleotide polymorphism (SNP) RT-qPCR assay to detect the N501Y mutation in banked SARS-CoV-2 RNA extracts (N=452) collected from December 2020 to April 2021. Of the SARS-CoV-2 positives (n=367), 22% carried the N501Y mutation and were classified as probable VOCs. This includes a sample that was confirmed to belong to the Beta lineage and was collected earlier than the first reported Beta variant in the country suggesting an earlier emergence of the variant. Validation experiments for the SNP RT-qPCR assay showed a limit of detection (LOD) of 3.01 copies/μL for both N501 and 501Y targets. A 99.35% concordance with partial S gene Sanger sequencing was observed confirming the presence of the N501Y SNP in 83 samples. In conclusion, the optimized SNP RT-qPCR assay serves as an important complementary or alternative tool for detecting probable SARS-CoV-2 variants, ensuring that samples ineligible for WGS are not overlooked. This effectively resolves sequencing gaps, including stringent sample acceptance criteria, extended TAT, and rigorous data analysis. Therefore, embracing this technology provides a rapid, economical, and dependable solution for managing pathogens of public health concern.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Institute for Tropical Medicine Institutional Review Board waived ethical approval for this work. The written informed consent requirement was waived based on the context of the emerging outbreak response.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
